A Comparative Study of Clobetasol Propionate (0.05%) Cream and Tacrolimus (0.1%) Ointment in the Management of Localised Vitiligo
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 7, Pages 2632-2638
Abstract
Background: To study and compare tacrolimus ointment (0.1%) and clobetasol propionate cream (0.05%) in the management of localised vitiligo. To know the common types of vitiligo, age and sex distribution and to know the percentage of regimentation and adverse effects encountered with tacrolimus ointments (0.1%) and clobetasol propionate cream (0.05%).Material and Methods:The present prospective study includes 50 cases of clinically diagnosed vitiligo attending the outpatient department of DVL, ACSR, Government General Hospital, Nellore from 01/06/2021 to 30/05/2022 over a period of 12 months. In this study patient with focal, local, segmental, lip-tip, mucosal and acrofacial vitiligo were included. Generalized and universal vitiligo (vitiligo vulgaris) were excluded in this study.
Results: In the present study 50 cases of vitiligo divided into two equal group treated with either tacrolimus ointment (0.1%) or clobetasol propionate cream (0.05%) were included. In this study the peak incidence of vitiligo is the age group of 21-30 years, with slight female preponderance (58%). Focal form of vitiligo in common (36%), response to clobetasol propionate cream (0.05%) 36 % whereas with tacrolimus ointment (0.1 %) it is 64 %. Adverse effects in clobetasol propionate cream (0.05%) were seen in 7 patients (28 %) and with tacrolimus in one patient (4 %).
Conclusion: In the present study clinical efficacy of tacrolimus ointment (0.1%) was almost equal to clobetasol propionate cream (0.05%) and tacrolimus ointment (0.1%) had fewer side effects than clobetasol propionate cream (0.05%) but the compliance was found to be better with clobetasol propionate cream (0.05%) due to its cost effectiveness.
- Article View: 36
- PDF Download: 136